NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma

被引：4
|
作者：
Griffiths, Christian [1 ]
Hay, Nicola [1 ]
Sutcliffe, Frances [1 ]
Stevens, Andrew [1 ]
机构：
[1] Natl Inst Hlth & Clin Excellence, Manchester, Lancs, England
来源：
LANCET ONCOLOGY | 2011年 / 12卷 / 03期
关键词：
INTERFERON ALPHA-2A; RANDOMIZED-TRIAL; MEDROXYPROGESTERONE; VINBLASTINE;
D O I：
10.1016/S1470-2045(11)70042-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：221 / 222
页数：2
相关论文
共 50 条
  • [11] New approaches to first-line treatment of advanced renal cell carcinoma
    George, Daniel J.
    Lee, Chung-Han
    Heng, Daniel
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [12] Cabozantinib Approved for First-Line Treatment of Advanced Renal Cell Carcinoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 96 - 96
  • [13] Bevacizumab - In first-line treatment of advanced and/or metastatic renal cell carcinoma
    Frampton, James E.
    Keating, Gillian M.
    BIODRUGS, 2008, 22 (02) : 113 - 120
  • [14] BevacizumabIn First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma
    James E. Frampton
    Gillian M. Keating
    BioDrugs, 2008, 22 : 113 - 120
  • [15] Patterns of care in renal cell carcinoma: Comparison of treatment duration for first-line sunitinib and pazopanib
    Garofalo, David
    Montgomery, Jim
    Drenning, Jason
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [16] First-line therapy in advanced renal cell carcinoma
    Rexer, H.
    Steiner, Th.
    Grunwald, V.
    UROLOGE, 2017, 56 (04): : 509 - 511
  • [17] First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience
    Lalani, Aly-Khan A.
    Li, Haocheng
    Heng, Daniel Y. C.
    Wood, Lori
    Kalirai, Austin
    Bjarnason, Georg A.
    Sim, Hao-Wen
    Kollmannsberger, Christian K.
    Kapoor, Anil
    Hotte, Sebastien J.
    Vanhuyse, Marie
    Czaykowski, Piotr
    Reaume, M. Neil
    Soulieres, Denis
    Venner, Peter
    North, Scott
    Basappa, Naveen S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (3-4): : 112 - 117
  • [18] COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UK
    Skentzou, E.
    Meng, J.
    Lister, J.
    Gray, L.
    VALUE IN HEALTH, 2018, 21 : S30 - S30
  • [19] Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study
    Masini, Cristina
    Vitale, Maria Giuseppa
    Maruzzo, Marco
    Procopio, Giuseppe
    de Giorgi, Ugo
    Buti, Sebastiano
    Rossetti, Sabrina
    Iacovelli, Roberto
    Atzori, Francesco
    Cosmai, Laura
    Vignani, Francesca
    Prati, Giuseppe
    Scagliarini, Sarah
    Guida, Annalisa
    Berselli, Annalisa
    Pinto, Carmine
    CLINICAL GENITOURINARY CANCER, 2019, 17 (01) : E150 - E155
  • [20] COST MINIMIZATION ANALYSIS OF USING PAZOPANIB IN FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Romero Prada, M. E.
    Celis, S.
    Alfonso Quinones, P. A.
    Acero, G.
    VALUE IN HEALTH, 2016, 19 (07) : A739 - A739
12345